Publications by Finn Wisløff
150 publications found
Original articles
Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma
Eur J Haematol, 87 (4), 330-7
DOI 10.1111/j.1600-0609.2011.01665.x, PubMed 21668504
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
Lancet Oncol, 11 (10), 973-82
DOI 10.1016/S1470-2045(10)70198-4, PubMed 20863761
Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma
Health Qual Life Outcomes, 8, 79
DOI 10.1186/1477-7525-8-79, PubMed 20678240
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
Blood, 116 (9), 1405-12
DOI 10.1182/blood-2009-08-237974, PubMed 20448107
Reduced nutritional status among multiple myeloma patients during treatment with high-dose chemotherapy and autologous stem cell support
Clin Nutr, 29 (4), 488-91
DOI 10.1016/j.clnu.2009.12.002, PubMed 20044183
What changes in health-related quality of life matter to multiple myeloma patients? A prospective study
Eur J Haematol, 84 (4), 345-53
DOI 10.1111/j.1600-0609.2009.01404.x, PubMed 20041946
[Is registration of multiple myeloma in the Norwegian Cancer Registry good enough?]
Tidsskr Nor Laegeforen, 128 (23), 2712-4
PubMed 19079417
Impaired nutritional status during intensive chemotherapy in Russian and Norwegian cohorts with acute myeloid leukemia
Leuk Lymphoma, 49 (10), 1916-24
DOI 10.1080/10428190802339723, PubMed 18949615
Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants
J Thromb Haemost, 5 (11), 2204-10
DOI 10.1111/j.1538-7836.2007.02734.x, PubMed 17958739
An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
Eur J Cancer, 43 (11), 1670-8
DOI 10.1016/j.ejca.2007.04.022, PubMed 17574838
Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study
Blood, 110 (4), 1178-83
DOI 10.1182/blood-2007-01-066043, PubMed 17440049
Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants
Br J Haematol, 136 (1), 131-7
DOI 10.1111/j.1365-2141.2006.06385.x, PubMed 17092306
Serum calcium is an independent predictor of quality of life in multiple myeloma
Eur J Haematol, 78 (1), 29-34
DOI 10.1111/j.0902-4441.2006.t01-1-EJH2887.x, PubMed 17038019
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation
Haematologica, 91 (9), 1228-33
PubMed 16956822
Detection and quantification of lupus anticoagulants in plasma from heparin treated patients, using addition of polybrene
Thromb J, 4, 3
DOI 10.1186/1477-9560-4-3, PubMed 16436199
Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes
Eur J Haematol, 75 (4), 293-8
DOI 10.1111/j.1600-0609.2005.00509.x, PubMed 16146535
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)
J Thromb Haemost, 3 (5), 848-53
DOI 10.1111/j.1538-7836.2005.01340.x, PubMed 15869575
Effect of subcutaneous administration of dalteparin on lupus anticoagulant assays
Thromb Res, 115 (6), 509-17
DOI 10.1016/j.thromres.2004.11.013, PubMed 15792683
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma
Br J Haematol, 125 (2), 149-55
DOI 10.1111/j.1365-2141.2004.04879.x, PubMed 15059136
Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences
Eur J Haematol, 72 (3), 172-80
DOI 10.1046/j.0902-4441.2003.00195.x, PubMed 14962235
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life
Br J Haematol, 120 (6), 1037-46
DOI 10.1046/j.1365-2141.2003.04153.x, PubMed 12648074
[Gaucher disease]
Tidsskr Nor Laegeforen, 123 (3), 304-7
PubMed 12640894
[National guidelines for treatment of chronic myelogenous leukemia]
Tidsskr Nor Laegeforen, 123 (2), 157-9
PubMed 12607495
Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
Blood, 100 (12), 3925-9
DOI 10.1182/blood-2002-05-1406, PubMed 12393395
Dilute prothrombin time-based lupus ratio test. Integrated LA testing with recombinant tissue thromboplastin
Thromb Res, 105 (2), 177-82
DOI 10.1016/s0049-3848(01)00420-0, PubMed 11958810
The evaluation of clotting times in the laboratory detection of lupus anticoagulants
Thromb Res, 104 (4), 275-82
DOI 10.1016/s0049-3848(01)00365-6, PubMed 11728529
[High dose therapy with autologous stem cell support--finally a progress in myelomatosis]
Tidsskr Nor Laegeforen, 121 (20), 2402-6
PubMed 11603051
Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma
Eur J Haematol, 66 (5), 328-36
DOI 10.1034/j.1600-0609.2001.066005328.x, PubMed 11422413
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support
Med Oncol, 18 (1), 65-77
DOI 10.1385/MO:18:1:65, PubMed 11778972
The Lupus Ratio test--an interlaboratory study on the detection of Lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test. Fifth International Survey of Lupus Anticoagulants--ISLA 5
Thromb Haemost, 83 (5), 704-8
PubMed 10823266
Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group
Acta Oncol, 39 (7), 809-13
DOI 10.1080/028418600750063550, PubMed 11145438
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group
Blood, 95 (1), 7-11
PubMed 10607678
Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors
Br J Haematol, 106 (4), 1005-12
DOI 10.1046/j.1365-2141.1999.01651.x, PubMed 10520004
[An anemia: without blood]
Tidsskr Nor Laegeforen, 119 (19), 2801
PubMed 10494197
Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor?
Thromb Res, 94 (4), 213-20
DOI 10.1016/s0049-3848(98)00195-9, PubMed 10336236
Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG)
Eur J Haematol, 62 (4), 271-7
DOI 10.1111/j.1600-0609.1999.tb01757.x, PubMed 10227461
Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life
Br J Haematol, 104 (3), 605-11
DOI 10.1046/j.1365-2141.1999.01206.x, PubMed 10086801
Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia
Acta Obstet Gynecol Scand, 78 (3), 191-7
DOI 10.1034/j.1600-0412.1999.780304.x, PubMed 10078579
Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken Scaling Model
Qual Life Res, 8 (1-2), 25-43
DOI 10.1023/a:1026419414249, PubMed 10457736
Compliance in quality of life data: a Norwegian experience
Stat Med, 17 (5-7), 623-32
DOI 10.1002/(sici)1097-0258(19980315/15)17:5/7<623::aid-sim809>3.0.co;2-5, PubMed 9549811
Preeclampsia and fetal growth retardation: Is there an association with antiphospholipid antibodies?
Hypertens. Pregnancy, 17 (1), 81-92
DOI 10.3109/10641959809072240
Plasma concentrations of Lp(a) lipoprotein and TGF-beta1 are altered in preeclampsia
Clin Genet, 52 (5), 371-6
DOI 10.1111/j.1399-0004.1997.tb04356.x, PubMed 9520129
Survival in 86 patients, aged 15-60, with primary acute myelogenous leukemia, treated with a common program in the Norwegian health regions I, III, IV and V in the period 1990-1995
Eur J Haematol, 59 (2), 110-4
DOI 10.1111/j.1600-0609.1997.tb00734.x, PubMed 9293859
Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial
Pharmacoeconomics, 12 (1), 89-103
DOI 10.2165/00019053-199712010-00009, PubMed 10169390
Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation
Acta Obstet Gynecol Scand, 76 (6), 541-6
DOI 10.3109/00016349709024580, PubMed 9246959
A simple procedure that increases the specificity of the activated protein C resistance test in samples containing antiphospholipid antibodies
Thromb Res, 86 (5), 385-91
DOI 10.1016/s0049-3848(97)00083-2, PubMed 9211629
Discrepancy between latex and ELISA D-dimer values in sepsis may be caused by human neutrophil elastase
Thromb Res, 86 (2), 141-52
DOI 10.1016/s0049-3848(97)00057-1, PubMed 9175235
Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group
Br J Haematol, 97 (1), 29-37
DOI 10.1046/j.1365-2141.1997.222667.x, PubMed 9136939
Increased levels of intercellular adhesion molecules and vascular cell adhesion molecules in pre-eclampsia
Br J Obstet Gynaecol, 104 (4), 466-70
DOI 10.1111/j.1471-0528.1997.tb11499.x, PubMed 9141584
Reduced C4b-binding protein in preeclampsia
Thromb Res, 85 (2), 153-8
DOI 10.1016/s0049-3848(96)00232-0, PubMed 9058489
Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group
Br J Haematol, 94 (2), 324-32
DOI 10.1046/j.1365-2141.1996.d01-1802.x, PubMed 8759893
False negative screening tests for lupus anticoagulants--an unrecognized problem?
Thromb Res, 82 (5), 445-51
DOI 10.1016/0049-3848(96)00094-1, PubMed 8771705
Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphoma
Bone Marrow Transplant, 17 (4), 577-81
PubMed 8722358
Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group
Br J Haematol, 92 (3), 604-13
DOI 10.1046/j.1365-2141.1996.352889.x, PubMed 8616024
Disseminated intravascular coagulation (DIC) in adult patients with acute leukaemia
Eur J Haematol, 54 (1), 34-8
DOI 10.1111/j.1600-0609.1995.tb01623.x, PubMed 7859873
An evaluation of two commercial test procedures for the detection of lupus anticoagulant
Am J Clin Pathol, 103 (1), 108-11
DOI 10.1093/ajcp/103.1.108, PubMed 7817935
Estimated 8-year survival of more than 40% in a population-based study of 79 adult patients with acute lymphoblastic leukaemia
Br J Haematol, 88 (1), 88-93
DOI 10.1111/j.1365-2141.1994.tb04981.x, PubMed 7803261
Choice of standard plasma for diagnosis and quantitation of lupus anticoagulants
Thromb Res, 72 (4), 287-94
DOI 10.1016/0049-3848(93)90137-d, PubMed 8303668
A quantitative, semi-automated and computer-assisted test for lupus anticoagulant
Thromb Res, 69 (2), 239-50
DOI 10.1016/0049-3848(93)90049-t, PubMed 8446953
Preparation of plasma for the detection of lupus anticoagulants and antiphospholipid antibodies
Thromb Res, 66 (1), 43-53
DOI 10.1016/0049-3848(92)90154-3, PubMed 1412182
Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke
Lancet, 339 (8791), 451-3
DOI 10.1016/0140-6736(92)91057-f, PubMed 1346819
Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Nordic Myeloma Study Group (NMSG)
Eur J Haematol, 48 (2), 70-4
DOI 10.1111/j.1600-0609.1992.tb00568.x, PubMed 1547878
Antiphospholipid antibodies in pre-eclamptic women: relation to growth retardation and neonatal outcome
Acta Obstet Gynecol Scand, 71 (2), 112-7
DOI 10.3109/00016349209007966, PubMed 1316037
Incidence and follow-up of asymptomatic multiple myeloma. The myeloma project of health region I in Norway. II
Eur J Haematol, 47 (5), 338-41
DOI 10.1111/j.1600-0609.1991.tb01857.x, PubMed 1761119
Has the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region I in Norway. I
Eur J Haematol, 47 (5), 333-7
DOI 10.1111/j.1600-0609.1991.tb01856.x, PubMed 1761118
Shared idiotypic determinant in mono- and polyclonal anti-phospholipid antibodies with lupus anticoagulant activity
Thromb Res, 61 (3), 201-11
DOI 10.1016/0049-3848(91)90096-f, PubMed 1902996
Quantitation of anticephalin antibodies in a computer-assisted enzyme-linked immunosorbent assay (ELISA): relation to lupus anticoagulant
Thromb Res, 57 (2), 235-46
DOI 10.1016/0049-3848(90)90323-5, PubMed 2107590
[Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside]
Tidsskr Nor Laegeforen, 109 (19-21), 2004-6
PubMed 2749689
[Splenectomy in hematologic diseases]
Tidsskr Nor Laegeforen, 109 (2), 201-3
PubMed 2916199
[Lupus anticoagulant. Coagulation inhibitor associated with thrombosis tendency]
Tidsskr Nor Laegeforen, 107 (13), 1128-30
PubMed 3111007
Monoclonal IgM with lupus anticoagulant activity in a case of Waldenström's macroglobulinaemia
Eur J Haematol, 38 (5), 456-60
DOI 10.1111/j.1600-0609.1987.tb01444.x, PubMed 3115822
Aclarubicin in the treatment of relapsed or resistant acute myelogenous leukaemia: a phase II trial
Eur J Haematol Suppl, 47, 43-7
DOI 10.1111/j.1600-0609.1987.tb00021.x, PubMed 3471524
The molecular localization of the ability of certain monoclonal immunoglobulins to interfere with fibrin polymerization
Thromb Res, 40 (4), 473-82
DOI 10.1016/0049-3848(85)90284-1, PubMed 4082120
[Severe aplastic anemia in adults. Therapeutic progress]
Tidsskr Nor Laegeforen, 105 (14), 966-8
PubMed 3892767
Effect of high-dose ampicillin and cloxacillin on bleeding time and bleeding in open-heart surgery
Scand J Thorac Cardiovasc Surg, 19 (1), 45-8
DOI 10.3109/14017438509102820, PubMed 4012240
[Diagnosis of hemoglobinopathies and thalassemia]
Tidsskr Nor Laegeforen, 104 (28), 1952-5
PubMed 6495285
Inhibition or acceleration of fibrin polymerization by monoclonal immunoglobulins and immunoglobulin fragments
Thromb Res, 35 (1), 81-90
DOI 10.1016/0049-3848(84)90315-3, PubMed 6474410
[Combination chemotherapy in Alkeran-resistant myelomatosis]
Tidsskr Nor Laegeforen, 104 (13), 873-4
PubMed 6463973
Effect of prophylactic high-dose treatment with ampicillin and cloxacillin on bleeding time and bleeding in patients undergoing elective vascular surgery
Scand J Haematol, 31 (2), 97-101
DOI 10.1111/j.1600-0609.1983.tb01515.x, PubMed 6612231
Sézary cells with an unusual phenotype, their modulation with 12-O-tetradecanoyl phorbol-13-acetate (TPA) in vitro, and their relationship to T-cell development
J Clin Immunol, 3 (3), 212-21
DOI 10.1007/BF00915345, PubMed 6604064
[Thermography in thrombosis. Used as a screening method in patients with suspected deep vein thrombosis]
Tidsskr Nor Laegeforen, 103 (6), 592-4
PubMed 6868033
CONGENITAL SPHEROCYTOSIS UNMASKED BY LYMPH-NODE TUBERCULOSIS
SCAND J HAEMATOL, 30 39, 19-21
COMPARISON OF STAINABLE IRON IN BONE-MARROW SMEARS AND NEEDLE MARROW BIOPSIES
SCAND J HAEMATOL, 30 39, 31-32
[Chronic pancreatitis as a cause to extrahepatic cholestasis]
Tidsskr Nor Laegeforen, 102 (26), 1325-7
PubMed 7164078
[Qualitative defects of blood platelets in clinical practice]
Tidsskr Nor Laegeforen, 102 (15), 842-5
PubMed 7157261
[Is serum ferritin of any use in the diagnosis of iron deficiency?]
Tidsskr Nor Laegeforen, 101 (22), 1177-9
PubMed 7281142
Prolonged bleeding time with adequate platelet count in hospital patients
Scand J Haematol, 27 (1), 45-50
DOI 10.1111/j.1600-0609.1981.tb00450.x, PubMed 7336158
Intestinal telangiectasis in Turner's syndrome
Endoscopy, 13 (2), 86-7
DOI 10.1055/s-2007-1021654, PubMed 6971752
[Hematological complications of alcohol abuse]
Tidsskr Nor Laegeforen, 100 (24), 1433-5
PubMed 7444888
Gastric involvement in herpes zoster
Endoscopy, 12 (3), 134-5
DOI 10.1055/s-2007-1021729, PubMed 7379763
Acquired stomatocytosis in alcoholic liver disease
Scand J Haematol, 23 (1), 43-50
DOI 10.1111/j.1600-0609.1979.tb02852.x, PubMed 493871
Haemolytic anaemia in alcohol abuse. A review of 14 cases
Acta Med Scand, 205 (3), 237-42
DOI 10.1111/j.0954-6820.1979.tb06037.x, PubMed 425850
HEMOLYTIC-ANEMIA IN ALCOHOL-ABUSE - REVIEW OF 14 CASES
Acta Med. Scand., 205 (3), 237-242
Role of cyclic nucleotides in human lymphocyte-mediated antibody-dependent cytotoxicity
Int Arch Allergy Appl Immunol, 53 (1), 42-9
DOI 10.1159/000231729, PubMed 190171
Abnormal lymphocyte populations in pure red cell aplasia
Scand J Haematol, 17 (4), 241-50
DOI 10.1111/j.1600-0609.1976.tb01181.x, PubMed 1087044
Different lymphocyte populations in rheumatoid arthritis and their relationship to anti-Ig activities
Ann Clin Res, 7 (3), 146-53
PubMed 1081361
Deficient lymphoid cell-mediated, PHA-induced cytotoxicity in rheumatoid arthritis patients
Scand J Immunol, 4 (3), 303-7
DOI 10.1111/j.1365-3083.1975.tb02630.x, PubMed 1080292
Lymphocyte subpopulations and immune reactions in rheumatoid inflammatory tissues
Scand J Rheumatol Suppl, 12, 77-88
PubMed 1084571
Lymphocyte subpopulations in rheumatoid arthritis
Rheumatology, 6, 231-41
PubMed 1081728
Structural requirements in the Fc region of rabbit IgG antibodies necessary to induce cytotoxicity by human lymphocytes
Scand J Immunol, 4 (1), 71-8
DOI 10.1111/j.1365-3083.1975.tb02601.x, PubMed 1079629
LYMPHOCYTE SUBPOPULATIONS AND IMMUNE-REACTIONS IN RHEUMATOID INFLAMMATORY TISSUES
Scand. J. Rheumatol., 5 12, 77-88
[Identification and characterization of a 3rd population of human lymphocytes with receptors for IgG (Fc-receptors)]
Medicina (B Aires), 35 (4), 355-68
PubMed 1196111
Lymphocyte populations and cellular immune reactions in juvenile rheumatoid arthritis
Scand J Immunol, 4 (8), 801-10
DOI 10.1111/j.1365-3083.1975.tb02689.x, PubMed 1082632
Selective defects of in vitro parameters of lymphoid cell function in patients with irradiated testicular tumour and in patients with lymphoproliferative disorders
Acta Pathol Microbiol Scand B Microbiol Immunol, 82 (2), 263-9
DOI 10.1111/j.1699-0463.1974.tb02321.x, PubMed 4546906
Inhibition of antibody-dependent human lymphocyte-mediated cytotoxicity by immunoglobulin classes, IgG subclasses, and IgG fragments
Scand J Immunol, 3 (1), 29-38
DOI 10.1111/j.1365-3083.1974.tb01230.x, PubMed 4857243
Characterization of subpopulations of human lymphoid cells participating in phytohemagglutinin and concanavalin A-induced cytotoxicity
Int Arch Allergy Appl Immunol, 47 (4), 488-97
DOI 10.1159/000231243, PubMed 4547156
SELECTIVE DEFECTS OF INVITRO PARAMETERS OF LYMPHOID-CELL FUNCTION IN PATIENTS WITH IRRADIATED TESTICULAR TUMOR AND IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS
ACTA PATH MICRO IM B, B 82 (2), 263-269
Antibody-dependent cytotoxicity mediated by human Fc-receptor-bearing cells lacking markers for B- and T-lymphocytes
Int Arch Allergy Appl Immunol, 47 (1), 139-54
DOI 10.1159/000231208, PubMed 4603056
Human lymphocytes with receptors for IgG. A population of cells distinct from T- and B-lymphocytes
Int Arch Allergy Appl Immunol, 47 (1), 124-38
DOI 10.1159/000231207, PubMed 4546531
Specificity of receptors for IgG on human lymphocyte-like cells
Scand J Immunol, 3 (4), 509-17
DOI 10.1111/j.1365-3083.1974.tb01284.x, PubMed 4137203
[Follow-up study of patients treated surgically for non-toxic goiter and thyrotoxicosis. A 1O year material]
Tidsskr Nor Laegeforen, 93 (16), 1223-5
PubMed 4800553
Antibody-dependent lymphocyte-mediated cytotoxicity in man: no requirement for lymphocytes with membrane-bound immunoglobulin
Scand J Immunol, 2 (2), 151-7
DOI 10.1111/j.1365-3083.1973.tb02026.x, PubMed 4542262
Studies on the cytotoxic activity of human lymphoid cells activated by concanavalin A
Int Arch Allergy Appl Immunol, 45 (3), 456-66
DOI 10.1159/000231063, PubMed 4542732
Hereditary thrombocytopenia with excessively prolonged bleeding time
Scand J Haematol, 6 (4), 250-61
DOI 10.1111/j.1600-0609.1969.tb02405.x, PubMed 5348279
Review articles
Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations
Eur J Haematol, 83 (4), 279-89
DOI 10.1111/j.1600-0609.2009.01303.x, PubMed 19558508
Guidelines on the diagnosis and management of multiple myeloma 2005
Br J Haematol, 132 (4), 410-51
DOI 10.1111/j.1365-2141.2005.05867.x, PubMed 16412016
[Antineoplastic agents targeting tyrosine kinases]
Tidsskr Nor Laegeforen, 125 (22), 3115-9
PubMed 16299568
Nordic Myeloma Study Group, the first 15 years: scientific collaboration and improvement of patient care
Eur J Haematol, 74 (3), 185-93
DOI 10.1111/j.1600-0609.2004.00379.x, PubMed 15693787
Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis
Thromb Res, 115 (1-2), 3-8
DOI 10.1016/j.thromres.2004.06.041, PubMed 15567446
Evidence-based treatment of the antiphospholipid syndrome: I. Pregnancy failure
Thromb Res, 114 (2), 75-81
DOI 10.1016/j.thromres.2004.05.006, PubMed 15306148
Laboratory diagnosis of the antiphospholipid syndrome
Thromb Res, 108 (5-6), 263-71
DOI 10.1016/s0049-3848(02)00400-0, PubMed 12676184
Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations
Pharmacoeconomics, 16 (4), 329-41
DOI 10.2165/00019053-199916040-00002, PubMed 10623362
[Measurement of health-related quality of life in malignant diseases. Does it have any consequences?]
Tidsskr Nor Laegeforen, 117 (26), 3812-6
PubMed 9417687
[Treatment with growth factors and cytokines in hematologic diseases]
Tidsskr Nor Laegeforen, 116 (12), 1465-9
PubMed 8650635
[Does social support have an impact on the prognosis in cancer?]
Tidsskr Nor Laegeforen, 115 (24), 3022-5
PubMed 7570530
[Phospholipid antibodies (lupus anticoagulant and cardiolipin antibodies). Detection and clinical significance]
Tidsskr Nor Laegeforen, 113 (18), 2269-72
PubMed 8362396
Other articles
[Close cooperation, but not oversteering]
Tidsskr Nor Laegeforen, 130 (6), 590-1
DOI 10.4045/tidsskr.10.0153, PubMed 20348990
[Leadership and academic competence]
Tidsskr Nor Laegeforen, 130 (6), 591
DOI 10.4045/tidsskr.10.0217, PubMed 20348994
[Research ethics and University of Oslo]
Tidsskr Nor Laegeforen, 128 (15), 1683-4
PubMed 18704143
[Epoetin in cancer treatment--the end of the game?]
Tidsskr Nor Laegeforen, 127 (18), 2359
PubMed 17895937
[Total survival as quality indicator]
Tidsskr Nor Laegeforen, 124 (23), 3096; author reply 3096
PubMed 15586201
[Financing of enzyme treatment in Gaucher disease]
Tidsskr Nor Laegeforen, 123 (3), 364
PubMed 12640908
[Use of blood from patients with hemochromatosis]
Tidsskr Nor Laegeforen, 121 (12), 1448
PubMed 11449762
[Should iron preparations be available only on prescription?]
Tidsskr Nor Laegeforen, 121 (9), 1155-6
PubMed 11354901
[Hereditary hemochromatosis and use of genetic tests]
Tidsskr Nor Laegeforen, 118 (12), 1911
PubMed 9638063
[Quality assurance in diagnosis and treatment of hematologic diseases]
Tidsskr Nor Laegeforen, 118 (2), 209
PubMed 9485610
Lupus anticoagulant and a functional assay for tissue factor pathway inhibitor
Thromb Res, 83 (4), 339-40
DOI 10.1016/0049-3848(96)00142-9, PubMed 8870178
Detection of lupus anticoagulant: an evaluation of routines for preparation and storage of plasma
Thromb Res, 79 (1), 135-40
DOI 10.1016/0049-3848(95)91522-m, PubMed 7495101
[High-dose therapy with autologous stem cell support in malignant diseases]
Tidsskr Nor Laegeforen, 114 (26), 3115
PubMed 7974434
[Treatment with high-dose cytostatic agents]
Tidsskr Nor Laegeforen, 114 (26), 3115-6
PubMed 7974435
[Recommendation to uncritical use of granulocyte colony-stimulating factor (G-CSF)?]
Tidsskr Nor Laegeforen, 112 (24), 3122
PubMed 1281932
ANTIPHOSPHOLIPID ANTIBODIES AND RECURRENT THROMBOOCCLUSIVE EVENTS - REPLY
Lancet, 340 (8811), 117-118
Antiphospholipid antibodies detected as anticephalin and anticardiolipin antibodies in patients with acute myocardial infarction: immunological response to myocardial necrosis?
Thromb Res, 59 (3), 675-80
DOI 10.1016/0049-3848(90)90427-e, PubMed 2237834
Inhibition of the tissue factor-factor VII mediated activation of coagulation factor X by a monoclonal IgM antibody expressing lupus anticoagulant activity
Thromb Res, 58 (3), 349-52
DOI 10.1016/0049-3848(90)90104-k, PubMed 2112789
[Antiphospholipid syndrome and lupus anticoagulant]
Tidsskr Nor Laegeforen, 110 (1), 94
PubMed 2300947
Cyclosporine in refractory severe aplastic anemia
N Engl J Med, 312 (18), 1193
DOI 10.1056/NEJM198505023121819, PubMed 3982483
Herpes zoster of the stomach
Lancet, 2 (8149), 953
DOI 10.1016/s0140-6736(79)92640-0, PubMed 91038
Schoolteachers and health in developing countries
Lancet, 2 (8088), 527
DOI 10.1016/s0140-6736(78)92252-3, PubMed 79895
Books
Utfordring og mulighet: en helsetjeneste i endring : eksempler fra norske sykehusog helsesamarbeidet Norge-Russland
Unipub, Oslo, 220 s.
BIBSYS 101210744, ISBN 978-82-303-1552-1
Theses
Studies on human lymphocyte cytotoxicity in vitro
Rikshospitalet, Institutt for generell og revmatologisk immunologi, Oslo, 1 b. (Flere pag.)
BIBSYS 011510390